Drug recall · September 8, 2021
Cyclobenzaprine Hydrochloride Tablets recall
Why: CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc. Fort Lauderdale, FL 33314, NDC 57237-266-01
- Lots / codes
1408824A, exp. date 08/2023 (labeler - Rising)
- Quantity
- 4,992 bottles
- Company
- Teva Pharmaceuticals USA, Parsippany, NJ
- Distribution
- Product was distributed nationwide.
- Initiated
- July 29, 2021 · Voluntary: Firm initiated
- Classified
- August 27, 2021
- Reported
- September 8, 2021
- Ended
- November 4, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cyclobenzaprine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.